Financial Report: Bristol-Myers Squibb 2Q

Bristol-Myers Squibb
 
2Q Revenues: $4.2 billion (+7%)

2Q Loss: $130 million (earnings were $330 million 2Q14)

FY Revenues: $8.2 billion (+7%)

FY Earnings: $1.1 billion (-17%)

Comments: Hepatitis C Franchise revenues were $479 million in the quarter driven by Daclatasvir. Sprycel sales were up 10% to $405 million. Orencia sales were up 15% to $461 million. Eliquis sales were $437 million compared to $171 in 2Q14. Baraclude sales were down 7% to $343 million; the Reyataz Franchise dropped 16% to $303 million; the Sustiva Franchise was down 12% to $317 million; and Abilify sales dropped 81% to $107 million, due to generic competition. U.S. revenues decreased 3% to $1.8 billion in the quarter. International revenues increased 17%. R&D expenses increased 31% to $1.9 billion in the quarter, primarily due to the acquisition of Flexus Biosciences, Inc.